Molecular diagnostics firm 3DMed Diagnostic announced on Monday the completion of a 1.5 billion yuan ($224 million) independent equity financing round — the second after it spun off from Chinese precision medicine developer 3D Medicines (3DMed) two years ago.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
